EA200100385A1 - COMPOSITION AND METHOD OF TREATMENT OF HEMOSTASIS DISORDER IN THE SUBJECT (OPTIONS) - Google Patents

COMPOSITION AND METHOD OF TREATMENT OF HEMOSTASIS DISORDER IN THE SUBJECT (OPTIONS)

Info

Publication number
EA200100385A1
EA200100385A1 EA200100385A EA200100385A EA200100385A1 EA 200100385 A1 EA200100385 A1 EA 200100385A1 EA 200100385 A EA200100385 A EA 200100385A EA 200100385 A EA200100385 A EA 200100385A EA 200100385 A1 EA200100385 A1 EA 200100385A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hemostasis
options
subject
treatment
composition
Prior art date
Application number
EA200100385A
Other languages
Russian (ru)
Other versions
EA005236B1 (en
Inventor
Гэри С. Грэй
Джиахуа Киан
Мэри Коллинс
Леон У. Хойэр
Original Assignee
Джинеткс Инститьют, Инк.
Эмерикэн Ред Кросс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинеткс Инститьют, Инк., Эмерикэн Ред Кросс filed Critical Джинеткс Инститьют, Инк.
Publication of EA200100385A1 publication Critical patent/EA200100385A1/en
Publication of EA005236B1 publication Critical patent/EA005236B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Представлены композиции и способы лечения нарушений гемостаза с использованием агентов, которые стимулируют гемостаз, и агентов, которые ингибируют костимулирующий сигнал в Т-клетке. Данные композиции и способы дают возможность лечить нарушения гемостаза с использованием чужеродных терапевтических белков при отрицательной модуляции иммунных ответов на терапевтические белки.Международная заявка была опубликована вместе с отчетом о международном поиске.Compositions and methods for treating hemostasis disorders using agents that stimulate hemostasis and agents that inhibit a costimulatory signal in a T-cell are presented. These compositions and methods make it possible to treat disorders of hemostasis using foreign therapeutic proteins with a negative modulation of immune responses to therapeutic proteins. The international application was published along with an international search report.

EA200100385A 1998-09-21 1999-09-21 Composition for treating and/or preventing disorders promoting hemostasis and method for treating such disorders EA005236B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (2)

Publication Number Publication Date
EA200100385A1 true EA200100385A1 (en) 2001-10-22
EA005236B1 EA005236B1 (en) 2004-12-30

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100385A EA005236B1 (en) 1998-09-21 1999-09-21 Composition for treating and/or preventing disorders promoting hemostasis and method for treating such disorders

Country Status (21)

Country Link
EP (1) EP1115423A1 (en)
JP (1) JP2002526455A (en)
KR (1) KR20010085830A (en)
CN (1) CN1331602A (en)
AU (1) AU761206B2 (en)
BR (1) BR9913991A (en)
CA (1) CA2343916A1 (en)
CZ (1) CZ20011021A3 (en)
EA (1) EA005236B1 (en)
HK (1) HK1039059A1 (en)
HU (1) HUP0103960A3 (en)
IL (1) IL142069A0 (en)
LT (1) LT4920B (en)
LV (1) LV12768B (en)
MX (1) MXPA01002898A (en)
NO (1) NO20011412L (en)
NZ (1) NZ511034A (en)
PL (1) PL346796A1 (en)
SI (1) SI20626A (en)
WO (1) WO2000016801A1 (en)
ZA (1) ZA200103156B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
WO2005010483A2 (en) * 2003-06-10 2005-02-03 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
DE3683980D1 (en) 1985-04-12 1992-04-02 Genetics Inst NEW PROCOAGULATION PROTEINS.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (en) 1990-02-05 1994-09-02 Tm Innovation PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
JPH10504310A (en) * 1994-08-19 1998-04-28 ノボ ノルディスク アクティーゼルスカブ How to treat a patient with a biologically active compound
CA2200869A1 (en) * 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
EE9900587A (en) * 1997-06-20 2000-08-15 Biogen, Incorporated CD154 blockade in therapeutic protein inhibitor syndrome
US8082673B2 (en) 2009-11-06 2011-12-27 Hexagon Metrology Ab Systems and methods for control and calibration of a CMM

Also Published As

Publication number Publication date
MXPA01002898A (en) 2002-06-04
NZ511034A (en) 2004-03-26
AU761206B2 (en) 2003-05-29
LT4920B (en) 2002-06-25
IL142069A0 (en) 2002-03-10
JP2002526455A (en) 2002-08-20
LV12768B (en) 2002-06-20
WO2000016801A1 (en) 2000-03-30
BR9913991A (en) 2001-07-03
CA2343916A1 (en) 2000-03-30
ZA200103156B (en) 2002-07-18
HK1039059A1 (en) 2002-04-12
PL346796A1 (en) 2002-02-25
AU6057899A (en) 2000-04-10
NO20011412L (en) 2001-05-16
LT2001045A (en) 2002-01-25
CZ20011021A3 (en) 2001-10-17
KR20010085830A (en) 2001-09-07
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (en) 2002-02-28
CN1331602A (en) 2002-01-16
WO2000016801A9 (en) 2000-10-26
HUP0103960A3 (en) 2003-09-29
EA005236B1 (en) 2004-12-30
LV12768A (en) 2001-12-20
NO20011412D0 (en) 2001-03-20
SI20626A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
EA199801044A1 (en) TISSUE REGENERATION MODULATORS
DE3751470D1 (en) Pentigetide for the treatment of non-IgE-mediated inflammatory diseases.
ATE330631T1 (en) ANTIBODIES FRAGMENTS FOR THE LOCAL TREATMENT OF EYE DISEASES
ATE279181T1 (en) USE OF 5HT-6 ANTAGONISTS TO TREAT ADHD
ATE241358T1 (en) USE OF CHOLINESTERASE INHIBITORS TO TREAT CONCENTRATION DISORDERS
DE69316948D1 (en) Soluble ligands for CD40
FI844510A0 (en) ENSYM-RESISTANT IMMUNSYSTEMET MODULERANDE PEPTIDER.
ATE326239T1 (en) METHODS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE IN SUCH METHODS
DE60312309D1 (en) USE OF BOTULINUM TOXIN TO TREAT HEART AND CIRCULAR DISEASES
DE69434218D1 (en) PHOTODYNAMIC TREATMENT OF SYNOVIUM
BR9607894A (en) Process for treating tumors
ATE245030T1 (en) ANTIGEN-PASSING HETEROPOLYMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING THEM
ATE74282T1 (en) METHOD OF TREATMENT OF PLASMA AND ITS PRODUCTS.
DE69703689T2 (en) THERAPEUTIC APPLICATIONS OF BPI PROTEIN PRODUCTS FOR TREATING HUMAN MENINGOCOCCÄMIA
DE69433243D1 (en) Use of ApoE to bind TAU and MAP2c proteins and to treat Alzheimer's disease
DE69633393D1 (en) AGENTS FOR TREATING AUTO-IMMUNE DISEASES
EA200100385A1 (en) COMPOSITION AND METHOD OF TREATMENT OF HEMOSTASIS DISORDER IN THE SUBJECT (OPTIONS)
DE60116075D1 (en) TREATMENT OF TUMORS WITH PHOTODYNAMIC THERAPY
ATE251462T1 (en) METHOD FOR TREATING SCAR TISSUE
DE69319341T2 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES RELATED TO DEFECTIVE IMMUNE FUNCTION
DE60144493D1 (en) METHOD FOR THE DETERMINATION AND TREATMENT OF TUBEROUS SCLEROSIS COMPLEX ASSOCIATED DISEASES
EA199901061A1 (en) NEW SALTS OF HRV-PEPTIDES WITH ORGANOPROTECTIVE ACTIVITY, METHOD OF THEIR RECOVERY AND THEIR USE IN THERAPY
DE69734349D1 (en) TREATMENT OF BONE DRESS WITH ADRENOMEDULLIN
ATE291434T1 (en) USE OF ANGIOTENSIN TO TREAT CANCER METASTASIS
ATE419348T1 (en) COMPOSITION AND METHOD FOR TREATING IMMUNE-RELATED DISEASES

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU